BridgeBio Pharma Inc (BBIO)
24.94
+0.46
(+1.88%)
USD |
NASDAQ |
Sep 27, 16:00
25.37
+0.43
(+1.72%)
After-Hours: 20:00
BridgeBio Pharma SG&A Expense (Annual): 150.59M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 150.59M |
| December 31, 2022 | 143.19M |
| December 31, 2021 | 192.21M |
| December 31, 2020 | 145.68M |
| Date | Value |
|---|---|
| December 31, 2019 | 94.35M |
| December 31, 2018 | 43.59M |
| December 31, 2017 | 13.30M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
94.35M
Minimum
2019
192.21M
Maximum
2021
145.21M
Average
145.68M
Median
2020
SG&A Expense (Annual) Benchmarks
| Alnylam Pharmaceuticals Inc | 795.65M |
| Pfizer Inc | 14.77B |
| Ionis Pharmaceuticals Inc | 232.60M |
| Johnson & Johnson | 20.11B |
| MediciNova Inc | 5.242M |